Cargando…
Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review
PURPOSE: Photobiomodulation therapy (PBT) has emerged as a possible treatment for age-related macular degeneration (AMD) and diabetic retinopathy (DR). This review seeks to summarize the application of PBT in AMD and DR. METHODS: The National Clinical Trial (NCT) database and PubMed were queried usi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421781/ https://www.ncbi.nlm.nih.gov/pubmed/34511875 http://dx.doi.org/10.2147/OPTH.S272327 |
_version_ | 1783749158847381504 |
---|---|
author | Muste, Justin C Russell, Matthew W Singh, Rishi P |
author_facet | Muste, Justin C Russell, Matthew W Singh, Rishi P |
author_sort | Muste, Justin C |
collection | PubMed |
description | PURPOSE: Photobiomodulation therapy (PBT) has emerged as a possible treatment for age-related macular degeneration (AMD) and diabetic retinopathy (DR). This review seeks to summarize the application of PBT in AMD and DR. METHODS: The National Clinical Trial (NCT) database and PubMed were queried using a literature search strategy and reviewed by the authors. RESULTS: Fourteen studies examining the application of PBT for AMD and nine studies examining the application of PBT for diabetic macular edema (DME) were extracted from 60 candidate publications. DISCUSSION: Despite notable methodological differences between studies, PBT has been reported to treat certain DR and AMD patients. DR patients with center involving DME and VA ≥ 20/25 have demonstrated response to treatment. AMD patients at Age-Related Eye Disease Study Stages 2–4 with VA ≥20/200 have also shown response to treatment. Results of major clinical trials are pending. CONCLUSION: PBT remains an emergent therapy with possible applications in DR and AMD. Further, high powered studies monitored by a neutral party with standard devices, treatment delivery and treatment timing are needed. |
format | Online Article Text |
id | pubmed-8421781 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84217812021-09-09 Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review Muste, Justin C Russell, Matthew W Singh, Rishi P Clin Ophthalmol Review PURPOSE: Photobiomodulation therapy (PBT) has emerged as a possible treatment for age-related macular degeneration (AMD) and diabetic retinopathy (DR). This review seeks to summarize the application of PBT in AMD and DR. METHODS: The National Clinical Trial (NCT) database and PubMed were queried using a literature search strategy and reviewed by the authors. RESULTS: Fourteen studies examining the application of PBT for AMD and nine studies examining the application of PBT for diabetic macular edema (DME) were extracted from 60 candidate publications. DISCUSSION: Despite notable methodological differences between studies, PBT has been reported to treat certain DR and AMD patients. DR patients with center involving DME and VA ≥ 20/25 have demonstrated response to treatment. AMD patients at Age-Related Eye Disease Study Stages 2–4 with VA ≥20/200 have also shown response to treatment. Results of major clinical trials are pending. CONCLUSION: PBT remains an emergent therapy with possible applications in DR and AMD. Further, high powered studies monitored by a neutral party with standard devices, treatment delivery and treatment timing are needed. Dove 2021-09-02 /pmc/articles/PMC8421781/ /pubmed/34511875 http://dx.doi.org/10.2147/OPTH.S272327 Text en © 2021 Muste et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Muste, Justin C Russell, Matthew W Singh, Rishi P Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review |
title | Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review |
title_full | Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review |
title_fullStr | Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review |
title_full_unstemmed | Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review |
title_short | Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review |
title_sort | photobiomodulation therapy for age-related macular degeneration and diabetic retinopathy: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421781/ https://www.ncbi.nlm.nih.gov/pubmed/34511875 http://dx.doi.org/10.2147/OPTH.S272327 |
work_keys_str_mv | AT mustejustinc photobiomodulationtherapyforagerelatedmaculardegenerationanddiabeticretinopathyareview AT russellmattheww photobiomodulationtherapyforagerelatedmaculardegenerationanddiabeticretinopathyareview AT singhriship photobiomodulationtherapyforagerelatedmaculardegenerationanddiabeticretinopathyareview |